AFAIK this is somewhat incorrect. Biotech switched to vaccine focus before SARS2 and the reason for the rapid development was the groundwork done for a SARS(1) vaccine.
It is also worth noting, the mRNA part wasn't the innovative technology, but the nano lipid vehicle allowing immune evasion and cell fusion.
Because of that, the SARS2 pandemic fast tracked the tech for numerous targets and will benefit cancer medicine as well as future vaccine developments.
It is also worth noting, the mRNA part wasn't the innovative technology, but the nano lipid vehicle allowing immune evasion and cell fusion.
Because of that, the SARS2 pandemic fast tracked the tech for numerous targets and will benefit cancer medicine as well as future vaccine developments.